Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces, economic factors, product availability, patent and other intellectual property protection, current and future branded, generic or over-the-counter competition, the regulatory process, and any developments following regulatory approval, among other uncertainties. For further details and a discussion of risks and uncertainties that may impact forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A, "Risk Factors" in the company's second quarter 2007 10-Q.

References:

1 ACTG 5211: Phase II study of the safety and efficacy of vicriviroc (VCV) in HIV-infected treatment-experienced subjects: 48 week results (TUAB102); International AIDS Society 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention; July 2007; Sydney, Australia.

2 NRTI - nucleoside reverse transcriptase inhibitor

3 NNRTI - non-nucleoside reverse transcriptase inhibitor

4 PI - protease inhibitor


'/>"/>
SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... Dec. 16 Verathon®, maker of ... announce that portable bladder volume ultrasound is ... guidelines for the Prevention of Catheter-Associated Urinary ... guidelines, introduced in early November 2009, replace ... 1981. The guidelines are located on ...
(Date:12/16/2009)... Dec. 16 According to Millennium Research ... market intelligence, health care reforms in China supported ... in 2009, and will continue to fuel growth ... Asia Pacific Markets for Interventional Cardiology Devices 2010 ... Chinese government will allow the Chinese drug-eluting stent ...
(Date:12/16/2009)... -- Greenway Medical Technologies, Inc. today announced that ... practice management and interoperability solution, Prime Suite® ... the annual 2009 Top 20 Best in ... report. ,, For practices having between six and ... Best in KLAS in ambulatory EMR for the ...
Breaking Medicine Technology:New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 2New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 3New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 4New 2009 CDC Guidelines for the Prevention of Catheter-Associated Urinary Tract Infections Include Bladder Volume Ultrasound 5Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 2Major Health Care Reforms in China Supported Growth of More Than 20% in the Drug-Eluting Stent Market in 2009, According to Millennium Research Group 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 2Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 3Greenway Medical Technologies' PrimeSuite Wins Three Best in KLAS Awards 4Micromet Announces Public Offering of Common Stock 13262 1Micromet Announces Public Offering of Common Stock 13262 2Micromet Announces Public Offering of Common Stock 13262 3Micromet Announces Public Offering of Common Stock 13262 4Osteotech Resumes Shipments of Bulgarian Tissue 13259 1Osteotech Resumes Shipments of Bulgarian Tissue 13259 2Osteotech Resumes Shipments of Bulgarian Tissue 13259 3PDL BioPharma to Present at BMO Capital Markets Healthcare Conference on August 5 2009 13256 1
... of non-animal alternative test methods , , ... announced that the ECVAM Scientific Advisory Committee (ESAC) endorsed the ... at its November meeting. ESAC concluded that the Modified ... of skin irritating and non-irritating test substances. , ...
... DCTH ) today announced the appointment of Pamela R. ... a proven corporate executive with extensive experience working with international and ... (LOGO: http://www.newscom.com/cgi-bin/prnh/20081118/NY46990LOGO ) , , ... served as CEO. Prior to starting Cobalt, she founded Xenogen ...
Other Medicine Technology:EpiDerm's Skin Irritation Test Fully Validated in European Union 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 2Delcath Adds Dr. Pamela R. Contag to Its Board of Directors 3
(Date:12/16/2009)... CHICAGO, Dec. 16 Allscripts (Nasdaq: ... its financial results for the three and six ... market opens on Monday, January 11, 2010. Allscripts ... to discuss the company,s earnings and other information ... morning. ,, (Logo: http://www.newscom.com/cgi-bin/prnh/20081013/AQM041LOGO ) ,, ...
(Date:12/16/2009)... HealthSciences Institute will sponsor a new learning ... organizations who serve individuals at risk of, ... health plan, medical home and other provider ... noncommercial webinars on topics, solutions and case ... care improvement. Each webinar will include a ...
(Date:12/16/2009)... Institute announce the first comprehensive analyses of cancer genomes. ... the DNA of cancer cells which are acquired during ... and a lung cancer, reveal for the first time ... cancers. , Lung cancer causes around one million deaths ... The number of mutations found suggest that a typical ...
(Date:12/16/2009)... Planet-Friendly Organics, Solar-Powered Manufacturing and Sustainable Packaging at an Affordable ... ... Angeles, CA (PRWEB) December 16, 2009 -- Actively healthy families ... all natural skin care for their children as Episencial ... featuring the beloved artwork of The Very Hungry Caterpillar from ...
(Date:12/16/2009)... leader of Digital Pen and Paper technology and the provider ... today announced that it is ranked among the Fastest Growing ... 2009. , ... (PRWEB) December 16, ... for the capture, digitalization and management of handwritten data. Kayentis ...
Breaking Medicine News(10 mins):Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 2Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 3Health News:Allscripts to Announce Second Quarter Fiscal 2010 Results 4Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 2Health News:New Learning Collaborative to Prepare Clinicians for Better Chronic Care 3Health News:Lung cancer and melanoma laid bare 2Health News:Lung cancer and melanoma laid bare 3Health News:Lung cancer and melanoma laid bare 4Health News:Lung cancer and melanoma laid bare 5Health News:Lung cancer and melanoma laid bare 6Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 2Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 3Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 4Health News:New from Episencial: All Natural, Actively Healthy Skin Care for Babies, Kids and Planet Features Eric Carle's "The Very Hungry Caterpillar" 5Health News:With a Revenue Growth of Over 500% During the Last 5 Years, Kayentis is Ranked on the Deloitte Technology Fast 500 -- EMEA 2009 2
... found that the Schering-Plough fungus-fighter drug - Noxafil, //which ... in protecting patients with crippled immune systems, according to ... of their study were published in the New England ... fungal infections, Noxafil, known generically as posaconazole, also seems ...
... Health Organization, Dr. Margaret Chan is very optimistic about dealing ... cites the case of measles to point out that with ... ,WHO reports released last week depict that deaths from measles ... by 75 percent in the past five years. ...
... proposals will fundamentally change the way that primary care ... to advance patient-centered// primary care were released today by ... report on The State of the Nation's Health Care. ... a collapse of primary care medicine, the ACP reported ...
... is ranked second in the list of ‘deadliest’ cancers, which ... to diagnose the disease in// the early stage. The Ontario ... program for colorectal cancer. This plan will adopt two crucial ... ,The envisaged five year screening program for men aged 50 ...
... the Department of Chemistry at the University of York have ... carbon// monoxide in treating disease. ,The Scientists have ... three-year study into the use of metal compounds for the ... ,Carbon monoxide is an anti-inflammatory, and they want to explore ...
... that point to yet another benefit of statins; improving survival ... for heart patients. They work by lowering the levels of ... arteries. ,The drugs have also been shown to ... heart disease from having a heart attack or stroke. ...
Other Medicine News:Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 2Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 3Health News:Benefits of Carbon Monoxide 2Health News:Statins Aid Survival in Lung Patients, Say Experts 2
... the durability of natural tissue ... of ingrowth and natural adaptation ... exceeds all applicable state and ... Tissue also reduces OR time ...
Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...
... The FineTech-Brindley (also known as the ... which has been used by people with ... (or urinate) on demand. A secondary use ... bowel evacuation and promote penile erection.,The Bladder ...
... Nephrostomy Balloon is used to dilate the ... nephrostomy tract during a percutaneous procedure. The ... from the balloon to the catheter shaft ... close approximation of the dilating tract to ...
Medicine Products: